ABSTRACT
Low-molecular-weight heparin (LMWH) is commonly administered as venous thromboembolism prophylaxis. The larger treatment dose indicated in acute coronary syndrome may be weight dependent. Heparin does not lyse clots but rather prevents them from forming or extending. Thrombolysis occurs continuously in the body; heparin merely arrests the clot-growing process enough for natural thrombolysis to triumph. In the event of haemorrhage, protamine sulphate reverses the effects of heparin.
